Celltrion Healthcare said that more than 10 U.S. insurers have included its Avastin biosimilar Vegzelma (ingredient: bevacizumab), indicated for in their formulary listings.Vegzelma is indicated to treat six types of cancer -- metastatic colorectal cancer; recurrent or metastatic non-squamous non-sm
SK Biopharmaceuticals has transferred the commercialization rights for the Middle East and North Africa (MENA) region for the epilepsy drug cenobamate (brand name in the U.S.: Xcopri) for just 4 billion won ($2.98 million).The amount is unusually small for a licensing-out of a U.S. FDA-approved new
In a decision aimed at reinforcing its position in the pharmaceutical industry, Celltrion Inc. has announced its plan to absorb its affiliate company, Celltrion Healthcare.Celltrion is listed on Kospi, and Celltrion Healthcare, Kosdaq. The established merger ratio stands at 1 : 0.4492620 (Celltrion
GC Cell said on Thursday that its U.S. affiliate, Artiva Biotherapeutics (Artiva), has received investigational new drug (IND) approval from the FDA for the phase 1 clinical trial of AB-101, an NK cell therapy for lupus nephritis (LN). This IND approval marks the first for an allogeneic CAR-T or NK
The 2023 Annual Meeting of the International Society for the Advancement of Spine Surgery, Asia-Pacific Section (ISASS AP 2023) opened on Wednesday for a four-day run at Conrad Hotel in Yeouido, Seoul.Korean organizers expressed hope that the conference will help speed up international cooperation t
Cellivery has received a “disclaimer” of opinion on the first half-year report from its auditor. The company's shares are suspended from trading, drawing the industry's attention to its delisting from the stock market.In a public notice on Monday, the new drug developer said it had received a “discl
Investment in bio and medical ventures in the first half of 2023 was less than half of the same period of last year.According to the Ministry of SMEs and Startups, investment in bio and medical ventures totaled 596.1 billion won ($448.1 million) in the first half of this year, down 54.7 percent from
Researchers from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) published a study revealing the mechanism responsible for the decline in intestinal function in patients with inflammatory bowel disease (IBD) caused by fine particulate matter (PM10).Fine particulate matter, commo
Samsung Biologics filed an injunction against Lotte Biologics and three of its former employees to stop them from moving to Lotte Biologics.Newsis, a local media outlet, reported that Samsung filed for an injunction against Lotte BioLogics and three former employees at the Seoul Eastern District Cou
Lotte Biologics said on Wednesday that it signed a memorandum of understanding (MOU) with Roche Diagnostics to advance its contract development and manufacturing (CDMO) business. Last month, Lotte Biologics signed a four-way memorandum of understanding (MOU) with Lotte Holdings, Incheon Metropolitan
A rare disease drug developed using artificial intelligence has been used in the clinical site to treat patients. Market expectations are high as it confirms the possibility of developing new drugs using AI.Pharos iBio said Thursday that it received approval for the therapeutic use of PHI-101, a tre
Samsung Bioepis is reportedly considering acquiring the biosimilar division of Biogen, according to industry sources Wednesday.Biogen put its biosimilar division up for sale to focus on developing new drugs, including Alzheimer's disease treatment Leqembi, earlier this year.If Samsung Bioepis decide
KoBioLabs has suspended the phase 2a clinical trial of its ulcerative colitis (UC) drug candidate KBL697 (pipeline name: KBLP-007).KoBioLabs said in a public notice last Wednesday that it had voluntarily withdrawn its phase 2a clinical trial of KBL697. In July 2021, KoBioLab received approval for it
Curocell has embarked on a new challenge of expanding indications aside from developing the first domestic CAR-T therapy.Curocel said Wednesday that it has completed administering the first patient group in the phase 1 clinical trial of its CAR-T therapy candidate, CRC01 (anbalcaptagin-otoryucel or
For the first time, Samsung Biologics surpassed 1.58 trillion won ($1.24 billion) in sales in the first half of 2023, driven by growth in its contract manufacturing organization (CMO) and biosimilar businesses.Samsung Biologics said Wednesday that it posted consolidated sales of 1.5871 trillion won
Celltrion said Wednesday that it has completed applying for the marketing approval of CT-P42, a biosimilar to Eylea (aflibercept) to treat ophthalmic diseases, to the Ministry of Food and Drug Safety.Based on CT-P42's global phase 3 clinical trial results, Celltrion has applied for marketing authori
Korean biopharmaceutical companies are entering the “senior business,” including medical and care services for older adults, preparing for the nation’s transition to a super-aging society.According to Statistics Korea, it is predicted that by 2025, the nation will enter a super-aged society where 20
Chong Kun Dang (CKD) Bio plans to reduce its workforce through an early retirement program (ERP) due to the deterioration of its performance caused by the Covid-19 outbreak, its CEO said on Monday.CKD Bio CEO Lee Jung-jin notified employees that the company's business situation was more difficult th
SK Biopharmaceuticals, the company behind the successful 2020 launch of epilepsy treatment cenobamate (U.S. product name: Xcopri) in the U.S., is now setting its sights on becoming a well-rounded big biotech enterprise.Speaking at a press conference on Tuesday, SK biopharmaceuticals CEO Lee Dong-hoo
SK Group said it has selected Brain Asset Management, a Korean private equity fund, as the preferred bidder for the pre-initial public offering (IPO) financing of its contract development and manufacturing organization (CDMO) subsidiary SK pharmteco.SK held the preliminary bidding round in May throu